Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Wallis, Carole L."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
    Autorzy:
    Salata RA; Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH, 44122, USA. .
    Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
    Ritz J; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
    Collier AC; University of Washington, Seattle, WA, USA.
    Hogg E; Social & Scientific Systems, A DLH Company, MD, Silver Spring, USA.
    Gross R; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
    Godfrey C; NIAID, Bethesda, MD, USA.
    Kumarasamy N; YR Gaitonde Center for AIDS Research and Education, Chennai, India.
    Kanyama C; University of North Carolina Project-Malawi, Lilongwe, Malawi.
    Mellors JW; University of Pittsburgh, Pittsburgh, PA, USA.
    Wallis CL; Lancet Laboratories and BARC SA, Johannesburg, South Africa.
    Hughes MD; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
    Pokaż więcej
    Corporate Authors:
    ACTG A5288 Study Team
    Źródło:
    AIDS research and therapy [AIDS Res Ther] 2023 Jan 05; Vol. 20 (1), pp. 3. Date of Electronic Publication: 2023 Jan 05.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
    MeSH Terms:
    Anti-HIV Agents*/therapeutic use
    HIV Infections*/drug therapy
    Humans ; Female ; Adult ; Male ; Reverse Transcriptase Inhibitors/therapeutic use ; Reverse Transcriptase Inhibitors/adverse effects ; Protease Inhibitors/therapeutic use ; Antiretroviral Therapy, Highly Active ; Anti-Retroviral Agents/therapeutic use ; CD4 Lymphocyte Count ; Viral Load ; RNA ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Autorzy:
    Avihingsanon A; HIV-NAT, Thai Red Cross AIDS Research Centre and Centre of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
    Hughes MD; Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
    Salata R; Case Western Reserve University, Cleveland, Ohio, USA.
    Godfrey C; Division of AIDS, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.
    McCarthy C; Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
    Mugyenyi P; Joint Clinical Research Center, Kampala, Uganda.
    Hogg E; Social & Scientific Systems, Inc., a DLH Holdings Company, Silver Spring, Maryland, USA.
    Gross R; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
    Cardoso SW; Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
    Bukuru A; Joint Clinical Research Center, Kampala, Uganda.
    Makanga M; Kenya Medical Research Institute/Center of Disease Control, Kisumu, Kenya.
    Badal-Aesen S; Clinical HIV Research Unit, Helen Joseph Hospital, University of Witwatersrand, Johannesburg, South Africa.
    Mave V; BJ Medical College Clinical Research Site, Pune, India.
    Ndege BW; Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Kenya.
    Fontain SN; Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti.
    Samaneka W; University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
    Secours R; Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti.
    Van Schalkwyk M; Family Centre for Research with Ubuntu (FAMCRU), Stellenbosch University, Cape Town, South Africa.
    Mngqibisa R; Durban International Clinical Research Site, King Edward Hospital, Enhancing Care Foundation, Durban, South Africa.
    Mohapi L; Soweto AIDS Clinical Trials Group, Clinical Research Site, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
    Valencia J; Barranco Clinical Research Site, Lima, Peru.
    Sugandhavesa P; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
    Montalban E; San Miguel Clinical Research Site, Lima, Peru.
    Munyanga C; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi.
    Chagomerana M; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi.
    Santos BR; Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil.
    Kumarasamy N; CART, Clinical Research Site, VHS Infection Disease Medical Centre, Chennai, India.
    Kanyama C; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi.
    Schooley RT; Division of Infectious Diseases, University of California, San Diego, California, USA.
    Mellors JW; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
    Wallis CL; BARC-South Africa and Lancet Laboratories, Johannesburg, South Africa.
    Collier AC; University of Washington School of Medicine, University of Washington, Seattle, Washington, USA.
    Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
    Pokaż więcej
    Corporate Authors:
    A5288 Study team
    Źródło:
    Journal of the International AIDS Society [J Int AIDS Soc] 2022 Jun; Vol. 25 (6), pp. e25905.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Anti-HIV Agents*/therapeutic use
    HIV Infections*/drug therapy
    HIV Protease Inhibitors*/therapeutic use
    HIV-1*/genetics
    Anti-Retroviral Agents/therapeutic use ; Darunavir/therapeutic use ; Female ; Humans ; Male ; Nitriles ; Pyrimidines ; RNA/therapeutic use ; Raltegravir Potassium/adverse effects ; Ritonavir/therapeutic use ; Viral Load
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
    Autorzy:
    Paredes R; IrsiCaixa AIDS Research Institute, Badalona, Spain.
    Tzou PL; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
    van Zyl G; Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa.
    Barrow G; Centre for HIV/AIDS Research, Education and Services (CHARES), Department of Medicine, University of the West Indies, Kingston Jamaica.
    Camacho R; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
    Carmona S; Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.
    Grant PM; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
    Gupta RK; UCL, Department of Infection, London, WC1E 6BT, United Kingdom.
    Hamers RL; Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.
    Harrigan PR; BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
    Jordan MR; Tufts University School of Medicine, Boston, MA, United States of America.
    Kantor R; Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, United States of America.
    Katzenstein DA; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
    Kuritzkes DR; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America.
    Maldarelli F; HIV Dynamics and Replication Program, CCR, National Cancer Institute, NIH, Translational Research Unit, Frederick, MD, United States of America.
    Otelea D; Molecular Diagnostics Laboratory, National Institute for Infectious Diseases, Bucharest, Romania.
    Wallis CL; BARC-SA and Lancet Laboratories, Johannesburg, South Africa.
    Schapiro JM; National Hemophilia Center, Tel Hashomer, Israel.
    Shafer RW; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2017 Jul 28; Vol. 12 (7), pp. e0181357. Date of Electronic Publication: 2017 Jul 28 (Print Publication: 2017).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Anti-HIV Agents/*pharmacology
    HIV-1/*drug effects
    HIV-1/*genetics
    Reverse Transcriptase Inhibitors/*pharmacology
    Alkynes ; Benzoxazines/pharmacology ; Cyclopropanes ; Dideoxynucleosides/pharmacology ; Drug Resistance, Viral/genetics ; Genotype ; Heterocyclic Compounds, 3-Ring/pharmacology ; Lamivudine/pharmacology ; Lopinavir/pharmacology ; Nelfinavir/pharmacology ; Oxazines ; Piperazines ; Pyridones ; Ritonavir/pharmacology ; Zidovudine/pharmacology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm.
    Autorzy:
    Rutstein SE; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Sarah_.; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Sarah_.
    Hosseinipour MC; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Project, Lilongwe, Malawi.
    Weinberger M; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Wheeler SB; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Biddle AK; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Wallis CL; BARC-SA and Lancet Laboratories, Johannesburg, South Africa.
    Balakrishnan P; YRG Centre for AIDS Research and Education (YRG CARE), Voluntary Health Services, Taramani, Chennai, 600113, India.
    Mellors JW; Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
    Morgado M; Department of STD, AIDS, and Viral Hepatitis, Brazilian National STD and AIDS Program, Rio de Janeiro, Brazil.
    Saravanan S; YRG Centre for AIDS Research and Education, Chennai, India.
    Tripathy S; Institute for Leprosy and Other Mycobacterial Diseases, Tajganj, Agra, India.
    Vardhanabhuti S; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
    Eron JJ; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Miller WC; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Pokaż więcej
    Źródło:
    BMC infectious diseases [BMC Infect Dis] 2016 Jun 13; Vol. 16, pp. 280. Date of Electronic Publication: 2016 Jun 13.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Algorithms*
    Risk Assessment*
    Viral Load*
    Anti-HIV Agents/*therapeutic use
    Drug Substitution/*statistics & numerical data
    HIV Infections/*drug therapy
    Adult ; Aged ; Area Under Curve ; Drug Resistance, Viral/physiology ; Female ; HIV Infections/virology ; HIV-1/physiology ; Humans ; Logistic Models ; Male ; Middle Aged ; ROC Curve ; Risk ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies